Clinical Trial Update: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations [Phase 3]

View source ↗

Summary

Phase 3 study comparing erdafitinib with vinflunine, docetaxel, or pembrolizumab in advanced urothelial carcinoma with FGFR gene alterations. The trial is activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Erdafitinib (erdafitinib)
• Pembrolizumab (pembrolizumab)
• Vinflunine (vinflunine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urothelial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-14